However, sarcoma cell lines and PDX tumors in vivo with high levels of MAP17 respond to the proteasome inhibitor bortezomib (Velcade, PS-341), approved by the FDA for the treatment of mantle cell lymphoma and multiple myeloma [33, 34]. Here, PDZK1IP1 is linked to plasma cell myeloma.